Santiago Rojas1,2, José Raúl Herance3,4, Juan Domingo Gispert5,6,7, Belén Arias8, Ignasi Miquel8, Ramón López8, Pilar Sánchez8, Esther Rincón8, Jesús Murat8. 1. Thrombotargets Europe S.L., Mediterranean Technology Park, Av. Canal Olímpic, s/n, Edif, B 6, 2ª, Castelldefels, 08860, Barcelona, Spain. santiagorojas@thrombotargets.com. 2. Unit of Human Anatomy and Embryology, Department of Morphological Sciences, Faculty of Medicine, Autonomous University of Barcelona, Cerdanyola Del Vallès, Spain. santiagorojas@thrombotargets.com. 3. Molecular Imaging Research Group-Vall d'Hebron Research Institute, CIBBIM-Nanomedicine, Barcelona, Spain. raul.herance@vhir.org. 4. Centro de Investigaci on Biom edica en Red de Bioingenierıa, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza, Spain. raul.herance@vhir.org. 5. Barcelonabeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain. 6. Centro de Investigaci on Biom edica en Red de Bioingenierıa, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza, Spain. 7. Pompeu Fabra University, Barcelona, Spain. 8. Thrombotargets Europe S.L., Mediterranean Technology Park, Av. Canal Olímpic, s/n, Edif, B 6, 2ª, Castelldefels, 08860, Barcelona, Spain.
Abstract
BACKGROUND AND OBJECTIVES: TT-173 is the first topical hemostatic agent based on tissue factor. To prevent thromboembolic events and intravascular coagulation it is necessary to rule out the systemic absorption of new bioactive hemostats. Here, we radiolabeled TT-173 with [18F]SBF to characterize its systemic absorption and biodistribution. METHODS: A group of rats were administered intravenously with [18F]TT-173 and were subjected to a positron emission tomography study. A second group of animals received the [18F]TT-173 topically over a skin lesion in the flank. Topical absorption was quantified and the biodistribution patterns observed were compared. RESULTS: After topical application, low amounts of [18F]TT-173 were absorbed and distributed without relevant accumulation in any organ. On the other hand, after intravenous injection, [18F]TT-173 accumulated in lungs, liver and spleen, consistent with intravascular clot formation and the posterior capillary trapping and phagocytosis by the reticuloendothelial system. In both cases, a substantial concentration of radioactive product was found in urine consistent with renal excretion of degradation products of [18F]TT-173. CONCLUSIONS: After topical application, [18F]TT-173 did not show a significant systemic accumulation in animal organs. Minor radioactive concentration found in lungs, liver and spleen likely corresponds with fragments of the product without procoagulant activity. Radiolabeling with [18F]SFB enables the characterization of systemic absorption and biodistribution of new topical hemostats like TT-173.
BACKGROUND AND OBJECTIVES:TT-173 is the first topical hemostatic agent based on tissue factor. To prevent thromboembolic events and intravascular coagulation it is necessary to rule out the systemic absorption of new bioactive hemostats. Here, we radiolabeled TT-173 with [18F]SBF to characterize its systemic absorption and biodistribution. METHODS: A group of rats were administered intravenously with [18F]TT-173 and were subjected to a positron emission tomography study. A second group of animals received the [18F]TT-173 topically over a skin lesion in the flank. Topical absorption was quantified and the biodistribution patterns observed were compared. RESULTS: After topical application, low amounts of [18F]TT-173 were absorbed and distributed without relevant accumulation in any organ. On the other hand, after intravenous injection, [18F]TT-173 accumulated in lungs, liver and spleen, consistent with intravascular clot formation and the posterior capillary trapping and phagocytosis by the reticuloendothelial system. In both cases, a substantial concentration of radioactive product was found in urine consistent with renal excretion of degradation products of [18F]TT-173. CONCLUSIONS: After topical application, [18F]TT-173 did not show a significant systemic accumulation in animal organs. Minor radioactive concentration found in lungs, liver and spleen likely corresponds with fragments of the product without procoagulant activity. Radiolabeling with [18F]SFB enables the characterization of systemic absorption and biodistribution of new topical hemostats like TT-173.
Authors: Hardean E Achneck; Bantayehu Sileshi; Ryan M Jamiolkowski; David M Albala; Mark L Shapiro; Jeffrey H Lawson Journal: Ann Surg Date: 2010-02 Impact factor: 12.969
Authors: Jonathan B Koea; Jonathan Batiller; Babahai Patel; Jessica Shen; Jeffrey Hammond; James Hart; Craig Fischer; O James Garden Journal: HPB (Oxford) Date: 2012-10-16 Impact factor: 3.647
Authors: A E Pusateri; J B Holcomb; S N Bhattacharyya; R A Harris; R R Gomez; M J MacPhee; J I Enriquez; A V Delgado; N C Charles; J R Hess Journal: J Trauma Date: 2001-01
Authors: Grant V Bochicchio; Navyash Gupta; Robert J Porte; Kenneth L Renkens; Piet Pattyn; Baki Topal; Roberto Ivan Troisi; William Muir; Ian Chetter; Daniel L Gillen; Linda A Zuckerman; Paul A Frohna Journal: J Am Coll Surg Date: 2014-10-13 Impact factor: 6.113
Authors: Giuseppe Nasso; Felice Piancone; Raffaele Bonifazi; Vito Romano; Giuseppe Visicchio; Carlo Maria De Filippo; Barbara Impiombato; Flavio Fiore; Francesco Bartolomucci; Francesco Alessandrini; Giuseppe Speziale Journal: Ann Thorac Surg Date: 2009-11 Impact factor: 4.330